Title |
Gemcitabine-induced cardiomyopathy: a case report and review of the literature
|
---|---|
Published in |
Journal of Medical Case Reports, June 2014
|
DOI | 10.1186/1752-1947-8-220 |
Pubmed ID | |
Authors |
Muhammad F Khan, Silvija Gottesman, Ravichandra Boyella, Elizabeth Juneman |
Abstract |
Newly developed antineoplastic drugs have resulted in improvements in morbidity and mortality from many forms of cancers. However, some of these new chemotherapeutic agents have potentially lethal side effects, which are now being exposed with their widespread use. Gemcitabine is a nucleoside analog, which is a commonly used agent for various solid organ malignancies. Phase 1 and 2 trials with gemcitabine did not show significant risk for cardiotoxicity; however, with its widespread clinical use over the last decade, a few cases of cardiotoxicity related to gemcitabine use have been reported. Cardiomyopathy after the use of gemcitabine monotherapy is extremely rare; and only one such case has been reported in detail previously. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 50% |
United Kingdom | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Scientists | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 3% |
Netherlands | 1 | 3% |
Portugal | 1 | 3% |
Unknown | 30 | 91% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 18% |
Student > Master | 6 | 18% |
Researcher | 4 | 12% |
Student > Bachelor | 2 | 6% |
Professor | 2 | 6% |
Other | 7 | 21% |
Unknown | 6 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 55% |
Agricultural and Biological Sciences | 4 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Neuroscience | 1 | 3% |
Other | 0 | 0% |
Unknown | 7 | 21% |